Early effects of mood stabilizers on the Akt/GSK-3β signaling pathway and on cell survival and proliferation
- 325 Downloads
Lithium, some of the anticonvulsants, and several second-generation antipsychotic drugs are common medications widely prescribed to treat bipolar disorder. Molecular targets and cellular events that mediate their effects have been described for these drugs but are only partially unraveled. Few comparative studies have been performed.
We evaluated seven mood stabilizers (MS) in the same in vitro system and found several differences and similarities in their cellular mechanisms (proliferation and cell survival). As some MS were previously shown to activate the Akt/GSK-3β axis, this pathway was explored for other drugs.
Materials and methods
The SH-SY5Y cells were cultured in RPMI-1640 medium. Effects of MS drugs on serum-induced cell proliferation and on slowing of cell death were analyzed. Phosphorylation and expression of Akt-1 and GSK-3β mRNA and protein were assessed for the seven drugs as well.
Lithium, Valproate, Olanzapine, and Clozapine enhance proliferation and protect cells against serum withdrawal-induced injury. These drugs also activate Akt-1 and GSK-3β phosphorylation. Interestingly, gene expression of Akt-1 mRNA and protein, but not GSK-3β, was increased. The other drugs Lamotrigine, Haloperidol, and Carbamazepine did not affect cellular events nor activate Akt/GSK-3β axis.
Valproate and atypical antipsychotics (Olanzapine and Clozapine) regulate SH-SY5Y cell proliferation and survival, activate the Akt/GSK-3β axis, and stimulate gene expression of Akt-1 mRNA and protein, as does Lithium. The other medications have no effect. The study shows the importance of the Akt/GSK-3 axis in MS actions but also pinpoints a different dependence of these drugs on this signaling axis.
KeywordsMood stabilizers SH-SY5Y cell proliferation Neuroprotection Akt–GSK-3β Signaling axis
The authors thank Mrs Pascale Marin for her technical support. All the experiments complied with the current laws of Switzerland.
- Aubry JM, Ferrero F, Schaad N (2007) Pharmachotherapy of bipolar disorders. J Wiley (ed.), ChesterGoogle Scholar
- Brunet A, Datta SR, Greenberg M (2001) Transcription-dependent and –independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 11:297–305Google Scholar
- Chen G, Hasanat KA, Bebchuk JM, Moore GJ, Glitz D, Manji HK (1999) Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. Psychosomatic Med 61:599–617Google Scholar
- Ciapparelli A, Dell'Osso L, Pini S, Chiavacci MC, Fenzi M, Cassano GB (2000) Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. J Clin Psychiatry 61:329–334Google Scholar
- Ciapparelli A, Dell'Osso L, Bandettini di Poggio A, Carmassi C, Cecconi D, Cassano GB (2003) Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry 64:451–458CrossRefGoogle Scholar
- Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995). Inhibition of glycogen synthase kinase-3 by insulin-mediated Protein kinase B. Nature 378:785–789Google Scholar
- Harwood AJ, Agam G (2003) Search for common mechanism for mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders. J Clin Psychiatry 64(Suppl 5):179–189Google Scholar
- Kahle PJ, Maas JW (1997) Use of CellTiter 96 reagents in semi automatic assay of neuronal survival. Neural Notes 3:12–14Google Scholar
- Karege F, Perroud N, Burkhardt S, Schwald M, Ballmann E, La Harpe R, Malafosse A (2007) Alteration in Kinase activity but not in protein levels of kinase B and glycogen synthase kinase-3β in ventral prefrontal cortex of depressed suicide victims. Biol Psychiatry 61:240–245PubMedCrossRefGoogle Scholar
- Li X, Zhu W, Roh MS, Friedman AB, Rosborough K, Jope RS (2004) In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 29:1426-31Google Scholar
- Manji HK, Moora GJ, Chen G (1999) Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry 46:949–940Google Scholar
- Zeng X, Tamai K, Doble B, Li S, Huang H, Habas R, Okamura H, Woodgett J, He X (2005) A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 438:873–877Google Scholar